These products are often referred to as compounded GLP-1 medications. SAHPRAs enforcement action On 23 May 2026, SAHPRA announced that it had intensified enforcement action against the unlawful manufacturing and distribution of unregistered GLP-1 and GIP medicines containing semaglutide, tirzepatide, or combination formulations
Klinic's comprehensive approach ensures you receive high-quality care with prior authorization support and ongoing assistance from our expert providers
Similar content being viewed by others Subjects Introduction Cardiovascular diseases are the leading cause of death globally 1
The activity of cytochrome P450 is known to generate ROS, perpetuating a vicious cycle of OS
Plantinga Y, Ghiadoni L, Magagna A, Giannarelli C, Franzoni F, Taddei S, Salvetti A
10.1007/s12640-012-9360-5 Neurotox Res